Olive Diagnostics News
13 articles
growth-positive
Instant urine tests can examine mental and physical health among the old and young | CTech
Olive Diagnostics, a health tech start-up, has developed a device that can analyze urine in real-time and provide health insights. The device, Olive KG 4.5 IoMT, is a non-invasive toilet lid that performs urine analysis to measure mental and physical health. The company received a $7.3 million Seed round last year and has paused orders due to high demand, with around 30,000 orders currently planned. The companys primary customers are assisted living facilities, homecare providers, and telemedicine platform operators. Olive Diagnostics recently won the Israeli regional finals of the Startup World Cup and will represent Israel in the global finals in San Francisco later this year.
CustomersInvestmentExpand
growth-positive
Israeli medtech startup Olive Diagnostics selected to join prestigious "Google for Startups Growth" program
Olive Diagnostics, an AI-based MedTech startup, has joined the Google for Startups Growth Academy. Olive Diagnostics is known for its Olive KG, a hands-free, non-invasive, AI-based optical device for urine analysis. The company has received the EU CE Marking for its medical device and has received orders from European organizations. As part of the Growth Academy: Health program, Olive Diagnostics will have access to Googles products, best practices, and connections to relevant stakeholders. The company has also announced a partnership with Mekorot, Israels national water company, to develop a mobile optical kit for detecting compounds in water sources. Olive Diagnostics has raised a total of $8.8 million in seed financing from various investors.
PartnersInvestment
growth-positive
Mekorot invests in Olive Diagnostics to monitor Kinneret pollution
Olive Diagnostics has been chosen by Mekorot Israel National Water company to develop an optical system for online analysis of chemical and biological compounds in water for the detection of threats to water safety. Mekorot will invest several million shekels in Olive Diagnostics for a small equity holding. The agreement aims to enhance monitoring of Israels water reservoirs. Olive Diagnostics technology will improve the monitoring of different water sources, enabling timely detection and treatment of hazardous contaminants. Mekorot has invested in eight startups, including Olive Diagnostics, in fields such as energy management, big data, cybersecurity, and water quality and security. Olive Diagnostics optical technology is attracting interest from various industries. Olive Diagnostics is a medical devices company that has developed the worlds first hands-free, non-invasive, AI-based optical device for urinalysis.
Partners
growth-positive
This Israel Based Startup 'Olive Diagnostics' has Launched an AI Powered Urinalysis Device that Saves Patients from Having to Pee in a Cup - Days Tech
Olive Diagnostics has launched an AI-powered urinalysis device called Olive KG, which can analyze a patients urine in real-time and provide data on various parameters. The device is toilet-mountable and uses optics to detect chemical elements in urine. It has potential medical applications and can also provide data on diet, exercise, and mental health for proactive lifestyle changes. The company has received the EUs CE Marking for its medical device. The article highlights the benefits of passive urinalysis devices compared to traditional stick tests. The launch of Olive Diagnostics in 2019 by CEO Guy Goldman and Corey Katz is mentioned.
CustomersPartners
growth-positive
Olive Diagnostics extends Seed round to $7.3 million for AI-powered real-time urine analysis device | CTech
Israeli startup Olive Diagnostics has received the CE Marking for its AI-powered optical urine analysis device. The company has extended its Seed funding round to $7.3 million, with an additional $1.5 million raised from existing and private investors. Olive Diagnostics flagship product, Olive KG, is an optical sensor-based device that performs real-time urine analysis and can be mounted on any toilet. The CE Marking allows the company to enter the European market, and it has already received first orders from two European organizations. Olive Diagnostics aims to transform medical care by providing non-invasive prevention and early disease detection.
InvestmentCustomers
growth-positive
חברת הסטארט-אפ Olive Diagnostics מרחיבה את סבב גיוס הסיד ל-7.3 מיליון דולר
Olive Diagnostics, a startup company, has expanded its funding round to $7.3 million. The European regulatory authority granted CE certification to Olive Diagnostics optical device that performs urine tests. As a result, the company received initial orders for the product from two European bodies. Olive Diagnostics raised $7.3 million, including an additional $1.5 million from existing investors and private investors. The companys investors in the early stages include Maccabi Healthcare Services, Mayo Clinic, eHealth Ventures, Amgen Ventures, the Innovation Authority, and private investors from the US and Europe. The companys product is an optical medical device called KG Olive, which is the worlds first AI-based optical device installed on a toilet. It continuously analyzes the molecular composition and characterization of the patients urine, enabling the detection of biological markers that may indicate medical problems and diseases. The device is equipped with IoMT capabilities and sends real-time secure personal data to the cloud and the treating physician.
Investment
growth-positive
"המצאנו מתמטיקה חדשה": האסלה שתעקוב אחרי הבריאות שלנו
Israeli start-up Olib Diagnostics has developed a system that uses spectroscopy to analyse urine and detect diseases. The system, which is installed in toilets, can identify red blood cells, proteins, ketones and creatinine, as well as monitor urine colour, pressure and density. The company has raised $4m in pre-seed and seed funding from investors including Maccabi Health Services and Cleveland Clinic, and is planning to seek approval for the product from the US Food and Drug Administration. The system is already installed in nursing homes in the Netherlands and is being piloted for home care patients by Maccabi.
Investment
growth-positive
Apple Watch now monitors your health with Israeli pee-analysis tech
Olive Diagnostics KG sensor, which analyzes urine for various biomarkers, can now communicate with the Apple Watch via the Olive WatchOS app. The app allows registered caregivers to track the health data of multiple users. The KG sensor can detect warning signs for over 600 medical conditions. Olive Diagnostics has raised $4 million in funding from various investors. The company aims to enable quick and early detection of conditions and diseases to reduce the burden on healthcare professionals.
PartnersInvestment
Texas Medical Technology invests in Olive Diagnostics, the World's First Hands-free, Toilet-mounted Urinalysis Device
growth-positive
Urine Analysis Enters Golden Era With World's First Hands Free Optical Sensor For The Toilet Targeting Early Detection Of Disease In The Elderly And Even Pregnant Women
Olive Diagnostics, a developer of optical sensors for urinalysis technology, has begun a funding round led by the Maccabi Foundation. The investment signals the demand for the companys non-invasive urinalysis device and data. Olive Diagnostics plans to initially target elder care homes and womens health clinics, with potential for expansion into aged-care systems and individual homes worldwide. The companys technology collects molecular and volumetric data from urine in real-time, providing critical information for medical diagnostics. The funding will support the development and deployment of Olive Diagnostics devices.
Investment
growth-positive
Keep track of your health by simply peeing as usual
Israeli startup Olive Diagnostics is developing a passive IoT device mounted in toilets that uses advanced optics to pick up biomarkers from urine. The device sends the results to a smartphone app, allowing users to monitor their health conveniently. The company plans to manufacture 500 devices for beta testing in geriatric facilities in Israel and Europe by the end of the year. The device will initially test for urinary tract infections, kidney stones, bladder infections, and hydration. After the beta trial, Olive Diagnostics plans to launch in the European market and expand its ability to identify and analyze more molecules indicative of medical conditions. The companys initial funding comes from Cleveland Clinic, Amgen, Israeli Innovation Authority, eHealth Ventures, and private investors.
Customers
growth-positive
Israeli startup turns your throne at home into a medical diagnostics tool
Israeli startup Olive Diagnostics has emerged from stealth with its K2 product, a remote diagnostics tool that detects urines molecular composition. The tool connects to the toilet bowl and generates secure, personalized diagnostic data linked via a mobile app. Users can monitor their own health, identify potential problems, and seek professional medical help if needed. Olive Diagnostics has already secured almost $2 million in seed funding from investors including Cleveland Clinic, Amgen, and the Israeli Innovation Authority. The company is preparing to attract investors for its Series A round.
InvestmentExpand
growth-positive
Olive Diagnostics exits Stealth Mode;delivers world's first consumer-use, hands-free, urinalysis solution
Olive Diagnostics has developed K2, a prototype that attaches to any toilet and provides complete diagnostics and health assessments. The device detects urines molecular composition and generates personalized diagnostic data linked to a mobile app. It aims to revolutionize in-home urinalysis by offering a convenient and non-invasive healthcare tool. Olive Diagnostics has secured initial funding from various investors and is now seeking additional funding for beta testing and production. The company plans to expand K2 into households and clinics worldwide. The article emphasizes the potential of K2 in disease prevention, early detection, and accurate intervention, as well as its ability to provide immediate and long-term health diagnostics. The investment opportunity is seen as promising.
Investment
